Member Info for arsenal58

Https://www.tipranks.com/news/the-fly/puretech-health-treatment-of-acute-myeloid-leukemia-granted-fda-orphan-status?utm_source=edition.cnn.com&utm_medium=referral

Ews & Insights

STOCKS

Zacks-Logo

Down -8.13% in 4 Weeks, Here's Why PureTech Health PLC Sponsored ADR (PRTC) Looks Ripe for a Turnaround

February 15, 2024 — 09:35 am EST

Written by Zacks Equity Research for Zacks ->

PureTech Health PLC Sponsored ADR (PRTC) has been beaten down lately with too much selling pressure. While the stock has lost 8.1% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.

Here is How to Spot Oversold Stocks

We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.

RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls

I get the impression the septics also expect this to boom 💥 big time

Sorry wrong link lol 😂

Https://www.stocktitan.net/news/PRTC/pure-tech-founded-entity-vor-biopharma-announces-vor33-granted-u-s-p16dz9cbnfia.html

It was there this morning ??

It was posted on the 29 of feb

Https://www.tipranks.com/

PureTech Health’s fully human anti-galectin-9 IgG4 monoclonal antibody was granted FDA orphan status as a treatment of Acute Myeloid Leukemia, according to a post to the agency’s website.

Published first on – the ultimate source for real-time, market-moving breaking financial news.

PureTech Health treatment of Acute Myeloid Leukemia granted FDA orphan status

WTF 😬

Huge trade gone through

Shell up for grabs ??

Barclays raises DS Smith price target to 420 (360) pence - 'overweight'

This looks nice 😊 lol 😂

Big call today

Https://oilprice.com/Latest-Energy-News/World-News/South-Africas-Platinum-Group-Miners-Are-In-Jeopardy.html

Https://oilprice.com/Latest-Energy-News/World-News/South-Africas-Platinum-Group-Miners-Are-In-Jeopardy.html

These shorters are not going to get caught for this divi

They will be buying back from the start of feb 1050 by exdivi day

If the management declare another whopper for June the shorters will be running like the wind 💨

Come on Rusty you know you want to do it please!!

As for the methane rules Biden will be long gone before it is implemented

If it carries on watch Texas apply to be the Lonestar state again

I feel sorry for any of you that are trapped from earlier last year

It could be time to buy again and get some profit on the way to ex divi day

GLA

PureTech Health PLC

NASDAQ: PRTC

OverviewFinancialsCompare

22.70 USD +4.07 (21.85%)today

22 Dec, 10:01 GMT-5 • Disclaimer

22.70 USD ‎10:01

ok thanks for the update

got back in this morning

will do the roller coaster again

this share has been good to me

****

PureTech retains its 3.1% equity ownership in Karuna.1 Additionally

Receive a 3% royalty from Karuna to Royalty Pharma on sales up to $2 billion annually, after which threshold Royalty Pharma will receive 33% and PureTech will retain 67% of the royalty payments. PureTech retains its 3.1% equity ownership in Karuna.1 Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals and 20% of sublicense income.

KarXT was invented by a team at PureTech, including its Chief Innovation Officer, Eric Elenko, Ph.D., who served as the founding CEO of Karuna Therapeutics. KarXT is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia as a monotherapy and adjunctive therapy and psychosis in Alzheimer’s disease. Karuna has announced that it plans to submit a New Drug Application for KarXT in schizophrenia to the U.S. Food and Drug Administration (FDA) in mid-2023.

Sills Cummis & Gross P.C., acted as legal advisors to PureTech and Gibson, Dunn & Crutcher, LLP, Jones Day and Maiwald GmbH acted as legal advisors to Royalty Pharma.

About PureTech’s Wholly Owned Pipeline

In addition to the excellent progress across its Founded Entities, PureTech’s Wholly Owned Pipeline is rapidly advancing, and the Company’s operational runway, including its $341.4 million Cash and Cash Equivalents as of June 30, 2022, not including this transaction, is expected to support this growth into the first quarter of 2026. PureTech’s pipeline is comprised of six therapeutic candidates, four of which are currently clinical stage, including one partnered program. These candidates are centered on a strategy of leveraging validated biology to rapidly advance therapeutics with proven efficacy. Several upcoming milestones are anticipated for these candidates, including the following:

LYT-100 (deupirfenidone) is in development for the potential treatment of conditions involving inflammation and fibrosis, including idiopathic fibrosis (IPF), for which current standards of care are associated with significant tolerability issues, resulting in approximately three out of four patients in the U.S. foregoing treatment with these otherwise efficacious medicines.2 LYT-100 is a deuterated form of one of the two standard of care treatments, pirfenidone, which has proven efficacy and has been shown to improve survival in these patients by approximately three years, but its side effects cause patients to discontinue or dose reduce, thereby limiting its effectiveness.3 LYT-100 has shown a 50% reduction in gastrointestinal tolerability issues in a head-to-head study versus pirfenidone, and it can be dosed at a higher exposure level, but with a lower Cmax, than the FDA-approved dosage of pirfenidone, potentially enabling improved efficacy. PureTech is currently evaluating two doses of LYT-100, one with comparable exposure to the approved dose o

Dallo

It seems they hold 3.1% of the Karuna equity still

after the deal with Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds.

PureTech retains its current equity stake in Karuna in addition to milestone payments and 20% of sublicense revenues due to PureTech.

Transaction provides further non-dilutive capital for PureTech’s growing and rapidly advancing Wholly Owned Pipeline, with five clinical-stage candidates expected by the end of 2023.

March 23, 2023 03:00 AM Eastern Daylight Time

BOSTON & NEW YORK--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, and Royalty Pharma (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences industry, today announced that Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT for up to $500 million, with $100 million in cash up front and up to $400 million in additional payments contingent on the achievement of certain regulatory and commercial milestones.

“We are delighted to partner with PureTech, which began a remarkable innovation story with KarXT that has demonstrated an impressive clinical profile in Phase 3,” said Pablo Legorreta, Royalty Pharma’s Founder and Chief Executive Officer. “We believe this important therapy will have a significant impact on patients with schizophrenia if approved by the FDA. This medicine is a notable addition to our royalty portfolio and is well aligned with our strategy of investing in breakthrough therapies that address areas of high unmet medical need.”

“We’ve seen extraordinary clinical success demonstrated by KarXT, which, if approved, will be the first new mechanism for treating schizophrenia in more than fifty years. KarXT has now demonstrated efficacy in registration enabling studies and is heralded as a potential treatment paradigm shift that could impact millions of patients,” said Daphne Zohar, Founder and Chief Executive Officer of PureTech. “This agreement will provide PureTech with additional non-dilutive capital to advance our Wholly Owned Pipeline, including our rapidly maturing clinical programs, towards potential commercialization. Such non-dilutive sources of capital have allowed us to fund our pipeline and operations without having to raise capital from the public markets in over five years, and we are pleased to be able to benefit from the success of our invented programs.”

As part of this transaction, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on sales up to $2 billion annually, after which threshold Royal

Carnival PLC (CUK) Reports Record Revenues and Positive Earnings Momentum

Full Year 2023 Earnings Highlight Strong Bookings and Revenue Growth

Author's Avatar

GuruFocus Research

14 hours ago

Summary

Record Revenues: Carnival PLC (CUK) achieved an all-time high with full year revenues of $21.6 billion.

Adjusted Net Income: Despite a U.S. GAAP net loss of $74 million, the company reported a positive adjusted net income of $1 million.

Debt Reduction: Carnival PLC (CUK) made significant debt payments totaling $6 billion, reducing its debt balance by $4.6 billion from its peak in Q1 2023.

Liquidity: The company ended the year with $5.4 billion in liquidity, positioning it strongly for future operations.

Booked Position: Entering 2024 with its best booked position on record for both price and occupancy.

Adjusted EBITDA: For the full year 2024, the company expects adjusted EBITDA of approximately $5.6 billion, indicating over 30% growth compared to 2023.

Article's Main Image

CUK

▲+5.81%

On December 21, 2023, Carnival PLC (CUK, Financial) released its 8-K filing, announcing a record-breaking fourth quarter and full year 2023 earnings, with continued strong bookings and earnings momentum. Carnival PLC (CUK), the largest global cruise company, operates a fleet of 90 ships across various brands, including Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn, among others. Prior to the pandemic, the company's brands attracted approximately 13 million guests in 2019, a level they aim to reach again in 2023.

Financial Performance and Challenges

Carnival PLC (CUK, Financial) reported record fourth quarter revenues of $5.4 billion, with net per diems and net yields in constant currency significantly exceeding 2019 levels. Full year revenues reached a historic high of $21.6 billion, with cash from operations at $4.3 billion and adjusted free cash flow at $2.1 billion. Despite a U.S. GAAP net loss of $74 million for the full year, the company achieved a positive adjusted net income of $1 million, outperforming its September guidance.

However, the company faced challenges, including a 4.6 percent decrease in gross margin yields and a 12 percent increase in cruise costs per available lower berth day (ALBD) compared to the fourth quarter of 2019. Adjusted cruise costs excluding fuel per ALBD increased by 11 percent, in line with September guidance. These cost increases reflect the impact of high cost inflation over the past four years.

Financial Achievements and Importance

The company's financial achievements, particularly the record revenues and strong bookings, are critical for Carnival PLC (CUK, Financial) as they demonstrate the company's ability to recover from the pandemic's impact and capitalize on the rebounding travel and leisure industry. The reduction in debt and increase in liquidity are also significant, as they improve the company's financial stability and ability to invest in future

Toot

Chance I am willing to take for a nice profit

If you think your idea is what will occur don’t buy

Myself I think 🤔 you are another scaremonger !!!?

All though i thought it would be more busy ??